Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 276 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR FDA Approves Ivosidenib for Advanced or Metastatic Cholangiocarcinoma August 30, 2021 Breast Cancer Development Spurred on by Prolactin Hormone, Studies Show April 28, 2021 FDA Approves Pralsetinib for RET-Altered Thyroid Cancers December 2, 2020 FDA Grants Accelerated Approval to Zongertinib for Non-squamous NSCLC with HER2... August 29, 2025 Load more HOT NEWS The Future Front Line: Pre-Med During COVID-19 Air Is Life: The Navajo Nation’s Historic Commercial Tobacco Ban FDA Approves Pembrolizumab for First-Line Treatment of MSI-H/dMMR Colorectal Cancer NGS Is Effective in Identifying Actionable Genetic Alterations for Investigational Targeted...
